Dong XR, Chen QQ, Xue ML, Wang L, Wu Q, Luo TF. Effect of polyene phosphatidylcholine/ursodeoxycholic acid/ademetionine on pregnancy outcomes in intrahepatic cholestasis. World J Clin Cases 2023; 11(27): 6431-6439 [PMID: 37900240 DOI: 10.12998/wjcc.v11.i27.6431]
Corresponding Author of This Article
Teng-Fei Luo, MD, Attending Doctor, Department of Obstetrics and Gynecology, Hangzhou Women's Hospital, No. 369 Kunpeng Road, Hangzhou 310016, Zhejiang Province, China. qiangzhuoxinliang@126.com
Research Domain of This Article
Medicine, General & Internal
Article-Type of This Article
Prospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Dong XR, Chen QQ, Xue ML, Wang L, Wu Q, Luo TF. Effect of polyene phosphatidylcholine/ursodeoxycholic acid/ademetionine on pregnancy outcomes in intrahepatic cholestasis. World J Clin Cases 2023; 11(27): 6431-6439 [PMID: 37900240 DOI: 10.12998/wjcc.v11.i27.6431]
Xiao-Rui Dong, Qian-Qian Chen, Meng-Ling Xue, Ling Wang, Qin Wu, Department of Obstetrics, Women’s Hospital School of Medicine Zhejiang University, Hangzhou 310000, Zhejiang Province, China
Teng-Fei Luo, Department of Obstetrics and Gynecology, Hangzhou Women's Hospital, Hangzhou 310016, Zhejiang Province, China
Author contributions: Dong XR and Chen QQ proposed the concept of this study; Xue ML and Wang L have contributed to data collection; Dong XR, Wu Q, and Luo TF contributed to formal analysis; Dong XR and Wu Q contributed to the investigation; Luo TF, Chen QQ, and Xue ML have contributed to these methods; Dong XR, Xue ML, Chen QQ, and Luo TF supervised the study; Wu Q validated this study; Dong XR and Wang L contributed to the visualization of this study; Dong XR and Luo TF wrote the first draft of the manuscript; Dong XR, Chen QQ, Xue ML, Wang L, Wu Q, Luo TF reviewed and edited the manuscript.
Institutional review board statement: This study has been approved by the Ethics Committee of the Obstetrics and Gynecology Hospital Affiliated to Zhejiang University School of Medicine.
Clinical trial registration statement: This study is registered at Clinical Hospital Center trial registry (https://www.researchregistry.com). The registration identification number is researchregistry8967.
Informed consent statement: This study has obtained informed consent from patients.
Conflict-of-interest statement: The authors declare no conflicts of interest.
Data sharing statement: All data generated or analyzed during this study are included in this published article.
CONSORT 2010 statement: The authors have read the CONSORT 2010 statement, and the manuscript was prepared and revised according to the CONSORT 2010 statement.
Corresponding author: Teng-Fei Luo, MD, Attending Doctor, Department of Obstetrics and Gynecology, Hangzhou Women's Hospital, No. 369 Kunpeng Road, Hangzhou 310016, Zhejiang Province, China. qiangzhuoxinliang@126.com
Received: June 14, 2023 Peer-review started: June 14, 2023 First decision: June 21, 2023 Revised: June 25, 2023 Accepted: July 14, 2023 Article in press: July 14, 2023 Published online: September 26, 2023 Processing time: 98 Days and 8.4 Hours
Core Tip
Core Tip: Intrahepatic cholestasis of pregnancy (ICP) can have negative effects on pregnancy outcomes, but the standard treatment with ursodeoxycholic acid and ademetionine is not always effective. This study aimed to evaluate the use of polyene phosphatidylcholine in combination with ursodeoxycholic acid and ademetionine for ICP treatment. The study involved 600 patients with ICP who were randomly assigned to receive either the standard dual-drug combination or the triple-drug combination including polyene phosphatidylcholine. The outcomes measured included bile acid levels, liver enzyme indices, and pregnancy outcomes. The results showed that the triple-drug combination was more effective in reducing pruritus scores, bile acid levels, and liver enzyme indices in comparison to the dual-drug combination. Additionally, the triple-drug group had a lower incidence of adverse pregnancy outcomes. Therefore, it can be concluded that the use of polyene phosphatidylcholine/ursodeoxycholic acid/ademetionine 1,4-butanedisulfonate is a safe and effective treatment option for ICP, although further clinical trials are necessary to confirm its clinical application.
